A Study of the Comparability of the Pharmacodynamic, Toxicological, and Pharmacokinetic Properties of the Reference Drug Pulmozyme® and the Biosimilar Drug Tigerase®.

The article presents the results of studies of the drug Tigerase® (inhalation solution manufactured by JSC GENERIUM, Russia), conducted to obtain evidence of its similarity (comparability) to the reference drug Pulmozyme® (inhalation solution, manufactured by Hoffmann-La Roche Ltd., Switzerland). Both drugs contain human recombinant deoxyribonuclease I (dornase alfa) as an active substance and are intended for the treatment of cystic fibrosis with pulmonary manifestations (mucoviscidosis).

[The separation, identification and molecular biologic analysis of isolates of pandemic influenza virus A(H1N1)pdm09].

The article presents data concerning analysis of bioassays under suspicion of influenza A(H1N1)pdm09. The technique of back transcription polymerase chain reaction and sequencing was applied. The separation of native influenza virus A was implemented using passaging through developing chick embryos.

[New oral anticoagulants for thromboprophylaxis under routine use of tranexamic acid after hip joint arthroplasty].

Purpose: To evaluate the efficacy and safety of the novel oral anticoagulants under conservative hemostasis with tranexamic acid in hip arthroplasty.

Material And Methods: All patients received 40 mg of enoxaparin 12 hours prior to surgery and on the operating day, and then they received either 10 mg of rivaroxaban (40 patients), 220 mg of dabigatran (42 patients) or 40 mng of enoxaparin (39 patients). Tranexamic acid with doses of 10 - 20 mg/kg was administered to all patients: within 30 minutes prior to surgery and 6 hours after the first infision.

[Study of Ingavirin antiviral activity against Mexican pandemic influenza virus A/H1N1/2009 in vitro and in vivo].

High in vitro and in vivo efficacy of Ingavirin against the Mexican pandemic influenza virus A/H1N1/2009, strains A/California/04/2009 (H1N1) and A/California/07/2009 (H1N1) vs. the reference drug Arbidol was studied and verified when used therapeutically and prophylactically.

[In vitro efficacy of ingavirin against the Mexican pandemic subtype H1N1 of influenza A virus, strains A/California/04/2009 and A/California/07/2009].

Ingavirin was shown to be efficient in inhibition of the influenza virus strains A/California/04/2009 and A/California/07/2009 (H1N1) in the MDCK cell culture. The coefficient of the cytopathic activity inhibition amounted to 50 and 60%, and the inhibition coefficients of the specific hemagglutinin formation were 50 and 50%, and 79,1 and 75% before and after the enrichment in chick embryos respectively.